Myriad Genetics stock hits 52-week low at $12.16 amid market challenges
Myriad Genetics , Inc. (NASDAQ:MYGN) stock has reached a new 52-week low, touching down at $12.16, as the company faces a challenging market environment. According to InvestingPro data, technical ...
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...
Nature21h
What went wrong at 23andMe? Why the genetic-data giant risks collapse
At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.
Myriad Genetics announces hereditary cancer risk assessment study published
Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening ...
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
Study showed online screening tool and patient education improved genetic testing completion rateSALT LAKE CITY, Jan. 21, ...